Venus Medtech (Hangzhou) Inc., established in July 2009 in Hangzhou, China, is the first and the only local Transcatheter Aortic Valve Implantation product provider in China, and one of the three providers in the world. The Company finished first-in-man study of self-expanding valve - Venus Pulmonary Valve (Venus P-Valve) system in Hanoi National Heart Center, Vietnam in March 2011, and got bench testing report from Medical Device Testing Center of CFDA medical device testing center in May 2011. TAVI saves lots of lives from traditional surgery. As the leader in this sector with unique technology, Venus has a promising future in the world. The Company was listed on the main board of the Hong Kong Stock Exchange on December 10, 2019 (stock code: 02500. hk).